Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$3.2b

Arcutis Biotherapeutics Future Growth

Future criteria checks 6/6

Arcutis Biotherapeutics is forecast to grow earnings and revenue by 48.8% and 21.8% per annum respectively. EPS is expected to grow by 48.6% per annum. Return on equity is forecast to be 27.3% in 3 years.

Key information

48.8%

Earnings growth rate

48.56%

EPS growth rate

Biotechs earnings growth23.1%
Revenue growth rate21.8%
Future return on equity27.26%
Analyst coverage

Good

Last updated14 Jan 2026

Recent future growth updates

Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Oct 31
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

May 09
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Recent updates

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Dec 09
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived

Dec 08

Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Oct 31
Results: Arcutis Biotherapeutics, Inc. Confounded Analyst Expectations With A Surprise Profit

Very Bullish

It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.

Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27%

Oct 02
Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27%

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

Jul 15
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load?

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

May 09
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
User avatar

FDA PDUFA Date And Payer Expansion Will Unlock Opportunity

Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential.

Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets

Apr 19

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute

Mar 12

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Mar 09
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations

Feb 26

Arcutis Biotherapeutics: After Outstanding 2024, Shares May Face Cooling Off Period

Jan 23

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jan 02
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump

Nov 27
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump

Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?

Nov 15

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Sep 23
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Aug 22

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Jul 17
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Earnings and Revenue Growth Forecasts

NasdaqGS:ARQT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028768293245N/A6
12/31/2027611181175N/A8
12/31/20264685293N/A8
12/31/2025358-2317N/A8
9/30/2025318-44-48-33N/A
6/30/2025263-93-81-65N/A
3/31/2025213-130-117-111N/A
12/31/2024197-140-117-112N/A
9/30/2024139-196-168-168N/A
6/30/2024132-199-177-177N/A
3/31/2024106-217-199-198N/A
12/31/202360-262-247-247N/A
9/30/202349-268-262-262N/A
6/30/202312-331-309-286N/A
3/31/20236-327-304-281N/A
12/31/20224-311-281-258N/A
9/30/20221-311-262-238N/A
6/30/2022N/A-260-212-212N/A
3/31/2022N/A-235-186-185N/A
12/31/2021N/A-206-176-175N/A
9/30/2021N/A-169-156-155N/A
6/30/2021N/A-150-149-148N/A
3/31/2021N/A-144-139-138N/A
12/31/2020N/A-136-113-113N/A
9/30/2020N/A-114-97-97N/A
6/30/2020N/A-90-74-74N/A
3/31/2020N/A-63-57-57N/A
12/31/2019N/A-42-43-43N/A
9/30/2019N/A-35-32-32N/A
6/30/2019N/A-28N/A-24N/A
3/31/2019N/A-23N/A-18N/A
12/31/2018N/A-19N/A-14N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARQT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).

Earnings vs Market: ARQT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARQT is expected to become profitable in the next 3 years.

Revenue vs Market: ARQT's revenue (21.8% per year) is forecast to grow faster than the US market (10.5% per year).

High Growth Revenue: ARQT's revenue (21.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ARQT's Return on Equity is forecast to be high in 3 years time (27.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/16 08:02
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcutis Biotherapeutics, Inc. is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Richard J. LawGoldman Sachs
null nullGuggenheim Securities, LLC